Agena Bioscience announces high-throughput, low-cost panel for molecular detection of SARS-CoV-2, Influenza A, and Influenza B


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Agena Bioscience announces high-throughput, low-cost panel for molecular detection of SARS-CoV-2, Influenza A, and Influenza B
Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or assay availability

Agena Bioscience, a global provider of low-cost and high-throughput molecular testing solutions, today announced the launch of the MassARRAY SARS-CoV-2/Flu Panel (RUO) for qualitative detection of SARS-CoV-2, influenza A, and influenza B viral RNA. The panel is available for research use only.

With unprecedented sample volumes expected, this flu season poses critical testing challenges for laboratories, which must reliably and efficiently differentiate between SARS-CoV-2 and influenza RNA.

"This flu season, many expect the demands on laboratories to further escalate as the pandemic persists. It is paramount that labs have access to testing that can accurately differentiate between SARS-CoV-2, influenza A, and influenza B viral RNA, without the need to reduce testing capacity or add resources," said Peter Dansky, CEO of Agena Bioscience. "The MassARRAY SARS-CoV-2/Flu Panel helps meet these challenges by offering laboratories a high-throughput, low-cost solution to support the continued increase in demand."

"Multi-respiratory viral detection will be critical to differentiate influenza from SARS-CoV-2 infections," said Dr Darryl Irwin, Vice President of Scientific Affairs. "The MassARRAY SARS-CoV-2/Flu Panel design includes a dual target assay for SARS-CoV-2 in addition to sophisticated assays that cover all flu A and flu B strains, enabling reliable detection and differentiation of these respiratory viruses."

With the panel's release, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or assay availability.

"Agena proactively sourced and secured materials, in order to provide uninterrupted product availability to our customers," explained Jason Halsey, Senior Vice President of Technology and Operations. "Agena's respiratory molecular detection kits and MassARRAY Systems are ready for immediate deployment and we are equipped to provide reliable supply on a continuing basis."

Tags : #AgenaBioscience #LatestNewsonAgenaBioscience2ndDec #LatestPharmaNews2ndDec #Pandemic #FluSeason #TestingCapacity

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026